What happened
On August 14, 2026, FDA updated its “Withdrawn | Cancer Accelerated Approvals” page. The page lists malignant hematology and oncology accelerated approval indications that were subsequently withdrawn and are “no longer FDA-approved.” Withdrawn indications are not listed until FDA publishes a Federal Register notice to that effect or updates product labeling.
The current list includes two Tazverik (tazemetostat) indications withdrawn on June 22, 2026. One covers adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, originally accelerated approved January 23, 2020. The other covers adult patients with relapsed or refractory follicular lymphoma, accelerated approved June 18, 2020, then withdrawn the same June 22, 2026 date. It also lists Xpovio (selinexor) for adult patients with relapsed or refractory diffuse large B-cell lymphoma after at least 2 lines of systemic therapy, accelerated approved June 22, 2020 and withdrawn April 30, 2026, alongside earlier withdrawals including Trodelvy, Exkivity, Truseltiq, Aliqopa, Pepaxto, Gavreto, Imbruvica, Blenrep, and Tecentriq.
Why it matters
This is not a new policy document, but it is a clear regulatory scorecard. FDA is maintaining a public record of oncology accelerated approvals that did not remain on the market in their original accelerated approval form. The 2026 additions show that the mechanism remains conditional in practice, not just in theory.
For drug developers, the likely read is straightforward: accelerated approval can still open the door, but the back end matters just as much. An indication can disappear years after its original approval. For investors, that should keep attention on the durability of any label built on accelerated approval, not just the initial approval event.
For payers and formulary teams, the practical implication is narrower but still relevant. FDA explicitly says these withdrawn indications are no longer FDA-approved and directs readers to Drugs@FDA for the latest approvals and prescribing information for specific products. That points toward a recurring operational issue in oncology: label status can change indication by indication, not necessarily product by product.
One thing to watch next is whether this list keeps expanding in 2026 and beyond. If it does, sponsors with accelerated approval oncology assets may face tougher commercial and valuation scrutiny well before any formal withdrawal lands. For broader drug policy context, see RxNews.ai. For detailed drug monographs, see ClinicalRx.ai.
